Page 103 - IMO-2-1

Innovative Medicines & Omics Subdural hematoma associated with avapritinib

Ethics approval and consent to participate 7. Zhang H, Liu Q. Prognostic indicators for gastrointestinal
stromal tumors: A review. Transl Oncol. 2020;13(10):100812.
Patient gave consent to participate in this study.
doi: 10.1016/j.tranon.2020.100812
Consent for publication 8. Reiter A, Schwaab J, DeAngelo DJ, et al. Efficacy and safety

Verbal consent has been obtained from the patient to of Avapritinib in previously treated patients with advanced
publish his data. systemic mastocytosis. Blood Adv. 2022;6(21):5750-5762.
doi: 10.1182/bloodadvances.2022007539
Availability of data
9. Joseph CP, Abaricia SN, Angelis MA, et al. Optimal
Not applicable. avapritinib treatment strategies for patients with metastatic
or unresectable gastrointestinal stromal tumors. Oncologist.
References 2021;26(4):e622-e631.
1. Suresh Babu MC, Chaudhuri T, Babu KG, et al. Metastatic doi: 10.1002/onco.13632
gastrointestinal stromal tumor: A regional cancer center
experience of 44 cases. South Asian J Cancer. 2017;6(3):118-121. 10. George S, Jones RL, Bauer S, et al. Avapritinib in
patients with advanced gastrointestinal stromal tumors
doi: 10.4103/sajc.sajc_290_16
following at least three prior lines of therapy. Oncologist.
2. Ahmed M. Recent advances in the management of 2021;26(4):e639-e649.
gastrointestinal stromal tumor. World J Clin Cases.
2020;8(15):3142-3155. doi: 10.1002/onco.13674
11. Li J, Zhang X, Deng Y, et al. Efficacy and safety of avapritinib
doi: 10.12998/wjcc.v8.i15.3142
in treating unresectable or metastatic gastrointestinal
3. Teuber A, Schulz T, Fletcher BS, et al. Avapritinib-based stromal tumors: A phase I/II, open-label, multicenter study.
SAR studies unveil a binding pocket in KIT and PDGFRA. Oncologist. 2023;28(2):187-e114.
Nat Commun. 2024;15(1):63.
doi: 10.1093/oncolo/oyac242
doi: 10.1038/s41467-023-44376-8
12. Gotlib J, Castells M, Elberink HO, et al. Avapritinib versus
4. Vallilas C, Sarantis P, Kyriazoglou A, et al. Gastrointestinal placebo in indolent systemic mastocytosis. NEJM Evid.
stromal tumors (GISTs): Novel therapeutic strategies 2023;2(6):EVIDoa2200339.
with immunotherapy and small molecules. Int J Mol Sci.
2021;22(2):493. doi: 10.1056/EVIDoa2200339
doi: 10.3390/ijms22020493 13. Hossain M, Habib I, Singha K, Kumar A. FDA-approved
heterocyclic molecules for cancer treatment: Synthesis,
5. Cao L, Tian W, Zhao Y, et al. Gene mutations in
gastrointestinal stromal tumors: Advances in treatment and dosage, mechanism of action and their adverse effect.
mechanism research. Glob Med Genet. 2024;11(4):251-262. Heliyon. 2023;10(1):e23172.
doi: 10.1055/s-0044-1789204 doi: 10.1016/j.heliyon.2023.e23172
6. Jones RL, Serrano C, von Mehren M, et al. Avapritinib 14. Rong L, Xie M, Jiang M, Qiu H, Kong L. A post-marketing
in unresectable or metastatic PDGFRA D842V-mutant pharmacovigilance study of Avapritinib: Adverse event
gastrointestinal stromal tumours: Long-term efficacy and data mining and analysis based on the United States Food
safety data from the NAVIGATOR phase I trial. Eur J and drug administration adverse event reporting system
Cancer. 2021;145:132-142. database. Br J Clin Pharmacol. 2024;90(8):1816-1826.
doi: 10.1016/j.ejca.2020.12.008 doi: 10.1111/bcp.15673

Volume 2 Issue 1 (2025) 97 doi: 10.36922/imo.7068